Xencor, Inc.
CTLA4-Ig immunoadhesins
Last updated:
Abstract:
The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
Status:
Grant
Type:
Utility
Filling date:
15 Apr 2021
Issue date:
22 Feb 2022